Work-In-Progress Seminar
Work-In-Progress Seminar
For the intensive exchange of information on the current state of the projects, all doctoral students will present and discuss the research results during the work-in-progress seminar in the presence of their supervisor team.
The work-in-progress seminar is combined with the scientific colloquium.
Winter Semester 2024/25
The colloquia & lectures will take place in lecture hall 6F starting at 4:30 pm.
Date & Speakers | Title |
---|---|
07.10.24 | GRK Progress Reports |
Alina Deipenbrock & Jitheesh Joy | |
04.11.24 | GRK Progress Reports |
Jia-Wey Tu & Lukas Biermann | |
25.11.24 | GRK Progress Reports |
Imke Bradtmöller & Christian Anzenhofer | |
09.12.24 | GRK Progress Reports |
Violetta Krisilia & Franziska Kinnen | |
20.01.25 | GRK Progress Reports |
Gürbüz Önder & Tobias Wassenberg |
Summer Semester 2024
The colloquia & lectures will take place in lecture hall 6H starting at 4:30 pm.
Date & Speakers | Title |
---|---|
13.05.24 | GRK Progress Reports |
Lena Pollmann & Svenja Oschem | |
27.05.24 | GRK Progress Reports |
Jingyu Li & Matthias Bleser | |
03.06.24 | GRK Progress Reports |
Alae-Eddine Moubsit & Adarsh Nair | |
17.06.24 | GRK Progress Reports |
Karina Krings & Céline David | |
01.07.24 | GRK Progress Reports |
Kira Tantsur & Christian Mammen | |
Winter Semester 2021/2022
The colloquia will start at 4:30 pm.
Date | Speakers | Title |
---|---|---|
04.10.21 | Dr. Christopher Stroh, Director Translational and Biomarker Research, Merck Group | A precision medicine approach to target the receptor tyrosine kinase MET in cancer |
18.10.21 | Information event on the Feodor Lynen Fellowship of the Alexander von Humboldt Foundation | |
25.10.21 | Prof. Dr. Heike Brötz-Oesterhelt, Interfaculty Institute of Microbiology and Infection Medicine, Microbial Bioactive Compounds, University Tübingen | Antibiotic Modes of Action - Technologies & Research Stories |
08.11.21 | Prof. Dr. Andreas Reichert, Institute of Biochemistry and Molecular Biology I, Heinrich-Heine-University Düsseldorf | Structure-function relations of mitochondria |
15.11.21 | Progress Reports | |
Julia Gottstein | Lantibiotic resistance in human pathogens | |
Mariam Dubiel | Histamine H4 receptors in cancer - perspectives as potential molecular target | |
29.11.21 | Progress Reports (lecture hall 5H) | |
Emmanuel Adeniyi | Characterization of molecular mechanisms underlying antimycobacterial activity of callyaerins | |
Xiaoli Yang | Beauvericin exhibits immunostimulatory effects on conventional dendritic cells via activating the TLR4 signaling pathwaysistant tumors and bacterial pathogens | |
06.12.21 | Dr. Jan Bülle, Kutzenberger Wolff & Partner, Partner, Dipl. Chem., Patentanwalt, European Patent & Trademark Attorney | Brief Introduction to the Patent System |
13.12.21 | Progress Reports (lecture hall 5H) | |
Moritz Klischan | Biaryl-based natural products as structural motif for pharmaceutically relevant compounds | |
Lena Berning | Characterization of autophagy-modulating natural products and derivatives for the elimination of therapy-resistant tumor cells | |
10.01.22 | Prof. Dr. Alice McHardy, Computational Biology of Infection Research, Helmholtz Centre for Infection Research | Critical Assessment of Metagenome Interpretation - the second round of challenges |
17.01.22 | Progress Reports (lecture hall 5H) | |
Marlena Sekeres | Modulation of the DNA damage response (DDR) by natural compounds (NC) to widen the therapeutic window of anticancer drugs | |
Pablo Cea | Structure based drug design against Nisin resistance systems | |
24.01.22 | Prof. Dr. Robin Teufel, Pharmaceutical Biology Division, Department of Pharmaceutical Sciences, University of Basel | Insights into the biosynthesis of bioactive bacterial tropone and polyketide natural products |
31.01.22 | Progress Reports (via Webex) | |
Fabian Fischer | Development of HDAC-inhibitors and HDAC-PROTACs | |
Flaminia Mazzone | Identification and characterization of new natural products with antimicrobial activity against Toxoplasma gondii |
Summer Semester 2021
The colloquia will take place as online meetings starting at 4:30 pm. The invitation link will be send by email.
Date | Speakers | Title |
---|---|---|
19.04.21 | Progress Reports | |
Flaminia Mazzone | Identification and characterization of new natural products with anti-microbial activity against Apicomplexa and multiresistant gram-negative rods (4MRGN) | |
Laura Mayer | Diversity-oriented synthesis of diaryl substituted heterocycles via sequential palladium catalysis | |
26.04.21 | Progress Reports | |
Pablo Cea | Structural studies of nisin resistance and immunity systems | |
Lars Seiffert | Synthesis of small-molecule inhibitors of nisin resistance protein | |
10.05.21 | Progress Reports | |
Julian Schliehe-Diecks | Characterization of synergy and resistance traits of HSP90 and HDAC inhibitors in leukemic cell lines | |
Fabian Fischer | Development of chemosensitizing HDAC-Inhibitors and HDAC-PROTACs | |
17.05.21 | Dr. Christine Beemelmanns, Junior Research Group Leader Chemical Biology of Microbe-Host Interactions, Leibniz Institute for Natural Product Research and Infection Biology e.V., Hans-Knöll-Institute (HKI) | Novel Secondary Metabolites from Microbial Interactions |
31.05.21 | Prof. Dr. Dominic Hoepfner, Director Genomic Sciences, Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research | How to catch a target: genetic fishing expeditions with natural products |
07.06.21 | Progress Reports | |
Korana Mudrovcic | Exploration of Strategies to Disrupt ULK1 Protein Complex and Chlorflavonin Optimization | |
Annabelle Friedrich | Targeting protein-protein interactions within the autophagy-inducing ULK1 complex for cancer therapy | |
14.06.21 | Dr. Bert Klebl, Managing Director and Chief Scientific Officer of Lead Discovery Center GmbH, Dortmund, Germany | Pandemic Prepardness – a Pathoblocker Concept to Inhibit S. aureus Induced Infections |
21.06.21 | Progress Reports | |
Talea Knak | Structural optimization of Chlorflavonin – a natural product with antimycobacterial activity | |
Ilka Hinxlage | Identification of Novel Apoptotic Signaling Pathways for the Elimination of Therapy-Resistant Tumors | |
28.06.21 | Dr. Elke Röhrdanz, Head of the Unit Reproductive and Genetic Toxicology, BfArM (Federal Institute for Drugs and Medical Devices) | Non-clinical Drug Development |
05.07.21 | cancelled | |
12.07.21 | Prof. Dr. Zoe Waibler, Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel | Batch testing and batch release of immunological biomedicines in Germany |